Loading
A phase 1/2 trial of GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer, melanoma, hepatocellular carcinoma and small-cell lung cancer, run by GV20 Therapeutics, now recruiting.
Study of GV20-0251 in Participants With Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT07070518 by GV20 Therapeutics, with 350 participants planned, started 2025-07-11 and due to reach its primary completion in 2027-07-16. Interventions recorded: GV20-0251.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GV20 Therapeutics, Endometrial cancer, Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/